Ideaya Biosciences Announces The Publication Of The Abstract For A Proffered Paper Session At The European Society Of Medical Oncology Congress 2023 Relating To Selected Data From Ongoing Phase 2 Trial Of Darovasertib Plus Crizotinib For Metastatic Uveal
Portfolio Pulse from Benzinga Newsdesk
Ideaya Biosciences has announced the publication of an abstract for a proffered paper session at the European Society of Medical Oncology Congress 2023. The abstract relates to selected data from an ongoing Phase 2 trial of Darovasertib plus Crizotinib for metastatic uveal.
October 17, 2023 | 10:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The announcement of the publication of an abstract related to Ideaya Biosciences' ongoing Phase 2 trial could potentially increase investor interest in the company.
The publication of the abstract indicates progress in Ideaya Biosciences' ongoing Phase 2 trial. This could potentially attract more investors, as it shows the company's commitment to advancing its clinical programs. Therefore, it could have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100